Estrogen recepter positive (ER+) invasive ductal cancers are the most common human breast malignancies and are grouped into Luminal A versus Luminal B tumors. Luminal B, as compared to Luminal A tumors, exhibit a higher proliferative capacity (io.e., high Ki-67), are poorly differentiated, and display a significant increased risk of recurrence. It is becoming increasingly clear that a subgroup of Luminal B tumors, which account for the most deaths from breast malignancies, exhibit an endocrine resistant tumor phenotype. Thus, it is proposed that this resistance observed in tumors exhibiting a loss of SIRT3 signature may explain the increased risk of a tumor recurrence in this subgroup of women who are actively on antihormonal therapy.
|Effective start/end date||9/1/15 → 8/31/19|
- Northwestern Memorial Hospital (Exhibit B.11)